Translating Cancer Research to Patients

Leap Therapeutics’ current clinical program includes product candidates targeting esophagogastric cancer, gynecologic cancer, biliary tract cancer, liver cancer, and other solid tumor malignancies. Details on our clinical trials are summarized below.

Therapeutic Candidate Target Trial Link Trial Description
Leap Therapeutics Clinical Trials
DKN-01 DKK1 NCT02013154

A study to evaluate the safety and tolerability of DKN-01 in combination with weekly paclitaxel in participants with refractory/recurrent esophageal, gastro-esophageal junction and gastric cancer

DKN-01 DKK1 NCT02375880

Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder

DKN-01 DKK1 NCT03395080

A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Relapsed/Refractory Endometrioid Endometrial or Endometrioid Ovarian Cancer

DKN-01 DKK1 NCT03645980 A Phase I/II Multicenter, Open-label Study of DKN-01 to Investigate the Anti-tumor Activity and Safety of DKN-01 in Patients With Hepatocellular Carcinoma and WNT Signaling Alterations
TRX518 GITR NCT01239134 Study of TRX518 in Stage III or IV Malignant Melanoma or Other Solid Tumors 
TRX518 GITR NCT02628574 Dose Escalation Study of TRX518 in Adults With Advanced Solid Tumors

Leap Therapeutics has partnered with EmergingMed to help patients find clinical trials that match their specific cancer diagnoses and treatment histories.  Please click here for Leap's Clinical Trial Navigation Service.